ReShape Lifesciences

About ReShape Lifesciences

ReShape Lifesciences is a premier weight-loss solutions company focused on offering an integrated portfolio of proven products and services to manage and treat obesity and metabolic diseases globally. Their mission is to deliver safe, effective, and sustainable therapies to address the growing health crises associated with obesity, diabetes, and hypertension.

Products & Services

LAP-BAND:An FDA-approved, minimally invasive, long-term treatment for obesity that does not alter anatomy and serves as an alternative to more invasive surgical procedures.

LAP-BAND 2.0 FLEX:An updated version of the LAP-BAND system for obesity treatment.

ReShape Vest:An investigational, minimally invasive medical device implanted laparoscopically to wrap around the stomach, mimicking the effects of weight-loss surgery without permanent anatomical changes. Not available for sale in the U.S.

ReShape Calibration Tubes:Tools used in obesity treatment procedures.

Obalon:A weight-loss solution offered by ReShape Lifesciences.

ReShapeCare™:A virtual tele-health weight-management program supporting lifestyle changes for sustained weight loss.

ReShape Optimize:A supplement product line associated with weight management.

Specialties

Obesity Treatment Weight-Loss Solutions Metabolic Disease Management Minimally Invasive Medical Devices

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 2600000 MR: - FA: $2.6 million FAN: 2600000	D: 2025-06-09 FD: 2025-06-09	-
2	RT: Public Offering T: - FT: Public Offering	A: 6000000 MR: - FA: $6.0 Million FAN: 6000000	D: 2025-02-15 FD: 2025-02-15	1 investors
3	RT: Grant T: - FT: Grant	A: 241000 MR: - FA: approximately $241,000 FAN: 241000	D: 2024-11-11 FD: 2024-11-11	1 investors
4	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 1200000 MR: - FA: $1.2 million FAN: 1200000	D: 2023-11-21 FD: 2023-11-21	1 investors
5	RT: Public Offering T: - FT: Public Offering	A: 3000000 MR: - FA: approximately $3.0 million FAN: 3000000	D: 2023-09-29 FD: 2023-09-29	-

Public Offering Latest

2025-06-09

$2.6M

Public Offering 2025-02-15

$6.0M

Grant 2024-11-11

$241K

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Paul F. Hickey

President and Chief Executive Officer

T

Tom Stankovich

Chief Financial Officer

N

Nick Ansari

Senior Vice President, Global Commercial Operations

A

Al Diaz

Vice President, Operations and R&D

D

Dov Gal

Vice President, Regulatory Clinical Quality & Compliance Officer

M

Michael Miller

View 3 more team members with Pro

Unlock Full Team Directory

Recent News